Synthetic Gene Medicines May Disrupt DNA Repair

Why It Matters

Unintended activation of DNA repair pathways could compromise genomic stability, affecting the safety profile of a growing class of gene medicines.

Key Takeaways

• ASOs bind DNA‑PKcs, ATM, PARP1.
• Binding creates nuclear “PS bodies” condensates.
• False repair signals arise without actual DNA damage.
• Clinical relevance uncertain; lower nuclear concentrations in patients.

Pulse Analysis

Antisense oligonucleotides have become a cornerstone of modern gene‑targeted therapeutics, with several products already approved for rare genetic disorders and dozens more in clinical pipelines. By pairing a short synthetic strand of nucleic acid to a complementary RNA target, ASOs modulate splicing, degrade transcripts, or block translation, delivering precise control over disease‑causing genes. The chemistry most often employed—phosphorothioate (PS) backbone modification—enhances nuclease resistance and cellular uptake, making it attractive for systemic administration. As the market for RNA‑based medicines expands, understanding off‑target effects is essential for maintaining therapeutic credibility.

The Karolinska study reveals that PS‑modified ASOs can directly engage three central DNA‑damage response proteins—DNA‑PKcs, ATM and PARP1—prompting their sequestration into dense nuclear condensates known as PS bodies. This interaction triggers a cascade that mimics genuine DNA injury, activating repair signaling pathways even when the genome is intact. Such artificial activation may interfere with the cell’s ability to prioritize genuine lesions, potentially fostering mutagenic events over time. The phenomenon appears at concentrations typical of in‑vitro experiments, highlighting a gap between laboratory conditions and therapeutic dosing.

From a regulatory perspective, the findings underscore the need for more rigorous safety assessments that include genomic stability endpoints for ASO candidates. Developers may need to redesign backbone chemistries, lower nuclear exposure, or incorporate mitigation strategies such as targeted delivery to reduce off‑target binding. Ongoing clinical data will be crucial to determine whether the observed in‑cell effects translate into measurable adverse outcomes in patients. Ultimately, integrating these insights early in drug design could preserve the rapid growth of the antisense market while safeguarding long‑term patient health.